A Comprehensive Review of the Integration of Biotechnology in Modern Medicine and Pathology: Advances in Diagnostic Techniques, Therapeutic Innovations, and Clinical Outcomes

Biotechnology in modern medicine and pathology encompasses molecular diagnostics, multi-omics analysis, nanotechnology-enabled platforms, digital pathology, bioinformatics, and computational approaches that support disease detection, therapeutic development, and clinical decision-making. This review examines how these technologies have contributed to diagnostic workflows, therapeutic development, disease classification, and clinical decision-making in contemporary healthcare. The integration of molecular biology, nanotechnology, and computational sciences has expanded the evaluation of disease-related processes such as genetic variation, biomarker expression, tumor heterogeneity, immune regulation, and molecular pathway alterations in conditions including cancer, inherited disorders, infectious diseases, cardiovascular disease, and autoimmune disease. Therapeutic innovations such as gene editing, nanomedicine, immunotherapy, biologics, and targeted drug delivery systems have further supported mechanism-based treatment strategies by improving tissue targeting, reducing off-target toxicity, and enabling more individualized therapeutic planning. Artificial intelligence (AI) and bioinformatics approaches, including machine learning, deep learning, computational pathology, digital whole-slide image analysis, and omics-data integration, have supported biomarker discovery, disease classification, diagnostic image analysis, risk stratification, and pathology-based clinical decision support. Additionally, molecular and digital pathology have improved disease subclassification and prognostic assessment by integrating histomorphologic findings with molecular and computational data. Despite these advances, high costs, technical complexity, data standardization challenges, infrastructure limitations, and ethical concerns continue to restrict widespread clinical adoption. Future work should prioritize low-cost point-of-care molecular and biosensor platforms for resource-limited settings, interoperable standards for omics and digital pathology data, multicenter prospective validation of AI-assisted diagnostic tools and nanomedicine-based therapies, transparent reporting of algorithm provenance, and regulatory pathways addressing data privacy, clinical accountability, and equitable access. Overall, biotechnology represents an important component of precision healthcare, with the potential to strengthen diagnostic accuracy, targeted therapy, disease monitoring, and patient-centered clinical outcomes.